Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors (vol 27, pg 3620, 2021)

被引：1
|
作者：
Curigliano, Giuseppe
Curigliano, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 17期
关键词：
D O I：
10.1158/1078-0432.CCR-24-2131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3957 / 3957
页数：1
相关论文
共 50 条
  • [41] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
    Yang, Yunpeng
    Zhao, Yuanyuan
    Fang, Wenfeng
    Huang, Yan
    Zhang, Yaxiong
    Ba, Yi
    Wang, Zhen
    Deng, Chao
    Hu, Desheng
    Wang, Wei
    Li, Guiling
    Luo, Suxia
    Fu, Zhichao
    Zhu, Haisheng
    Wang, Huili
    Zhao, Shiwei
    Li, Tao
    Cai, Charles
    Zhang, Li
    CANCER RESEARCH, 2024, 84 (07)
  • [42] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Lin, Chia-Chi
    Garralda, Elena
    Schoeffski, Patrick
    Hong, David S.
    Siu, Lillian L.
    Martin, Miguel
    Maur, Michela
    Hui, Rina
    Soo, Ross A.
    Chiu, Joanne
    Zhang, Tian
    Ma, Brigette
    Kyi, Chrisann
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Sarantopoulos, John
    Weickhardt, Andrew
    Carvajal, Richard D.
    Spratlin, Jennifer
    Esaki, Taito
    Rolland, Frederic
    Akerley, Wallace
    Deschler-Baier, Barbara
    Rispoli, Lawrence
    Samant, Tanay S.
    Chowdhury, Niladri Roy
    Gusenleitner, Daniel
    Kwak, Eunice L.
    Askoxylakis, Vasileios
    De Braud, Filippo
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [43] PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
    Lim, Michael
    Ye, Xiaobu
    Nabors, Burt
    Piotrowski, Anna F.
    Fisher, Joy
    Desideri, Serena
    Sims, Megan
    Wen, Patrick
    Grossman, Stuart A.
    NEURO-ONCOLOGY, 2017, 19 : 31 - 31
  • [44] Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1
    Carneiro, Ana
    Yachnin, Jeffrey
    Aljumaily, Raid
    Abel, Edvard
    Falchook, Gerald Steven
    Ji, Yan
    Borggren, Marie
    Martensson, Linda
    Gertsson, Susanne
    Karlsson, Ingrid
    Teige, Ingrid
    Tehranchi, Ramin
    Wallin, Johan Erik
    Chisamore, Michael Jon
    Frendeus, Bjorn
    McAllister, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors
    Tolcher, Anthony
    Hong, David
    Sullivan, Ryan
    Mier, James
    Shapiro, Geoffrey
    Pearlberg, Joseph
    Brail, Les
    Kharidia, Jahnavi
    Han, Lixin
    Ullmann, Claudio Dansky
    Stern, Howard M.
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [46] Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
    Desai, Jayesh
    Voskoboynik, Mark
    Markman, Ben
    Hou, Jeannie
    Zeng, Dewan
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC
    Zhu, Hengrui
    Zhang, Jinhui
    Yan, Han
    Ding, Xiao
    Yang, Juan
    Jiang, Yu
    Deng, Minjuan
    Song, Haoxuan
    Ping, Fangfang
    Sun, Fuyun
    Li, Xiaoyu
    Zhang, Lijie
    Jiang, Bin
    Song, Weiwei
    Shen, Zhirong
    Jin, Wei
    Zhang, Jiyuan
    Zhang, Yun
    CANCER RESEARCH, 2024, 84 (06)
  • [48] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [49] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [50] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
12345